1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Comparison of patients with and without distal embolization
Total (n = 91)Distal Embolization (n = 15)No Distal Embolization (n = 76)P Value
Mean age (years)67 ± 1560 ± 1368 ± 16.16
Male/female48 (53%)6 (40%)45 (59%).28
Occlusion site.58
    MCA48 (53%)6 (40%)42 (55%)
    ICA29 (32%)6 (40%)23 (30%)
    ACA2 (3%)0 (0%)2 (3%)
    BA12 (13%)3 (20%)9 (12%)
Study protocol*.00
    Group 147 (52%)2 (13%)45 (59%)
    Group 212 (13%)6 (40%)6 (8%)
    Group 319 (21%)4 (27%)15 (20%)
    Group 413 (14%)3 (20%)10 (13%)
Mean time to treatment (hours)4.36 ± 2.184.59 ± 3.134.31 ± 1.97.14
Initial Qureshi grade 0–3B53 (58%)6 (40%)47 (62%).12
Initial Qureshi grade 4A-538 (42%)9 (60%)29 (38%)
Final recanalization†.48
    None19 (21%)2 (13%)17 (22%)
    Partial41 (45%)8 (50%)33 (43%)
    Complete29 (32%)3 (19%)26 (34%)
Symptomatic ICH (No., %)103 (21)c6 (8).12
Median initial NIHSS score19 (±8)19 (±8)19 (±8).98
Mean 24-hour NIHSS score18 ± 1324 (±15)17 (±12).07
Mean 7-day NIHSS score18 ± 1621 (±17)18 (±16).46
Favorable 1- to 3-month mRS‡ (No., %)29 (32%)2 (13%)27 (36%).09
Favorable 1–3 mRS at 1–3 months among treatment responders§24/70 (34%)23/24 (96%)1/11 (9%).05
  • Note:—MCA indicates middle cerebral artery; ICA, internal carotid artery; ACA, anterior cerebral artery; BA, basilar artery; ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Score.
  • * Group 1, IA reteplase and MDT; group 2, EKOS MicroLysUS North American trial; group 3, MDT following IV thrombolysis; group 4, IA reteplase and IV abciximab (FDA IND 9180).
  • † Defined as ≤ 2.
  • ‡ Data were missing for 1 patient.
  • § Patients who never demonstrated recanalization were excluded from the analysis.